

Kaoru Tsuchiya

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7389659/publications.pdf>

Version: 2024-02-01

29
papers

1,096
citations

516215

16
h-index

476904

29
g-index

29
all docs

29
docs citations

29
times ranked

1578
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy. PLoS ONE, 2022, 17, e0264075.	1.1	2
2	Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma. PLoS ONE, 2022, 17, e0265235.	1.1	4
3	Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study. Cancers, 2022, 14, 2975.	1.7	5
4	Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial. Liver Cancer, 2022, 11, 558-571.	4.2	6
5	The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study. Cancers, 2021, 13, 2608.	1.7	34
6	Prognosis of intrahepatic cholangiocarcinoma stratified by albuminâ€“bilirubin grade. Hepatology Research, 2021, 51, 902-908.	1.8	11
7	Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease. Journal of Medical Ultrasonics (2001), 2021, 48, 481-487.	0.6	11
8	Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2960-2966.	1.4	36
9	Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup. International Journal of Molecular Sciences, 2021, 22, 40.	1.8	8
10	Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinib. Hepatology Research, 2020, 50, 137-143.	1.8	19
11	Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis. Hepatology Research, 2020, 50, 1375-1385.	1.8	22
12	Early radiological response evaluation with response evaluation criteria in solid tumors 1.1 stratifies survival in hepatocellular carcinoma patients treated with lenvatinib. JGH Open, 2020, 4, 1183-1190.	0.7	6
13	Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not Î±-fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor. International Journal of Molecular Sciences, 2020, 21, 3640.	1.8	5
14	Validation of albumin, bilirubin, and platelet criteria for avoiding screening endoscopy in patients with advanced fibrosis. Hepatology Research, 2020, 50, 996-999.	1.8	5
15	Use of the Serum Wisteria floribunda Agglutinin-Positive Mac2 Binding Protein as a Marker of Gastroesophageal Varices and Liver-Related Events in Chronic Hepatitis C Patients. Diagnostics, 2020, 10, 173.	1.3	8
16	Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. PLoS ONE, 2020, 15, e0231828.	1.1	42
17	Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease. Scientific Reports, 2019, 9, 10109.	1.6	24
18	Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinomaâ€“Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice. Cancers, 2019, 11, 1517.	1.7	30

#	ARTICLE	IF	CITATIONS
19	Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 1256.	1.7	17
20	Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , 2019, 26, 893-899.	1.0	25
21	<i>Wisteria floribunda</i> agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus. <i>Hepatology Research</i> , 2018, 48, 1131-1139.	1.8	40
22	Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0154558.	1.1	34
23	Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinoma. <i>Hepatology Research</i> , 2015, 45, E130-40.	1.8	13
24	<i>Wisteria floribunda</i> agglutinin positive human Mac-2 binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. <i>Hepatology Research</i> , 2015, 45, E82-8.	1.8	55
25	Non-alcoholic fatty liver disease fibrosis score and FIB-4 scoring system could identify patients at risk of systemic complications. <i>Hepatology Research</i> , 2015, 45, 667-675.	1.8	26
26	Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan. <i>Liver International</i> , 2015, 35, 1581-1589.	1.9	30
27	JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. <i>Liver Cancer</i> , 2014, 3, 458-468.	4.2	512
28	Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients. <i>Journal of Gastroenterology</i> , 2014, 49, 1495-1503.	2.3	44
29	Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients. <i>Hepatology Research</i> , 2014, 44, 720-727.	1.8	22